Proton Pump Inhibitors in Pediatrics
Open Access
- 20 March 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pediatric Drugs
- Vol. 15 (2), 119-131
- https://doi.org/10.1007/s40272-013-0012-x
Abstract
Proton pump inhibitors (PPIs) have become some of the most frequently prescribed medications for treatment of adults and children. Their effectiveness for treatment of peptic conditions in the pediatric population, including gastric ulcers, gastroesophageal reflux disease (GERD), and Helicobacter pylori infections has been established for children older than 1 year. Studies of the preverbal population of neonates and infants have identified doses that inhibit acid production, but the effectiveness of PPIs in the treatment of GERD has not been established except for the recent approval of esomeprazole treatment of erosive esophagitis in infants. Reasons that have been proposed for this are complex, ranging from GERD not occurring in this population to a lack of histologic identification of esophagitis related to GERD to questions about the validity of symptom scoring systems to identify esophagitis when it occurs in infants. The effectiveness of PPIs relates to their structures, which must undergo acidic activation within the parietal cell to allow the PPI to be ionized and form covalent disulfide bonds with cysteines of the H+–K+-adenosine triphosphatase (H+–K+-ATPase). Once the PPI binds to the proton pump, the pump is inactivated. Some PPIs, such as omeprazole and rabeprazole bind to cysteines that are exposed, and their binding can be reversed. After irreversible chemical inhibition of the proton pump, such as occurs with pantoprazole, the recovery of the protein of the pump has a half-life of around 50 h. Cytochrome P450 (CYP) 2C19 and to a lesser degree CYP3A4 clear the PPIs metabolically. These enzymes are immature at birth and reach adult levels of activity by 5–6 months after birth. This parallels studies of the maturation of CYP2C19 to adult levels by roughly the same age after birth. Specific single nucleotide polymorphisms of CYP2C19 reduce clearance proportionally and increase exposure and prolong proton pump inhibition. Prolonged treatment of pediatric patients with PPIs has not caused cancer or significant abnormalities.Keywords
This publication has 60 references indexed in Scilit:
- Randomized, Open-Label, Multicentre Pharmacokinetic Studies of Two Dose Levels of Pantoprazole Granules in Infants and Children Aged 1 Month through <6 Years with Gastro-Oesophageal Reflux DiseaseClinical Pharmacokinetics, 2011
- A Multicenter, Randomized, Open-Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux DiseaseThe Journal of Clinical Pharmacology, 2011
- Pantoprazole for Symptoms of Infant GERD: The Emperor Has No Clothes!Journal of Pediatric Gastroenterology and Nutrition, 2010
- Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential EffectPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2010
- Pharmacodynamics and Systemic Exposure of Esomeprazole in Preterm Infants and Term Neonates with Gastroesophageal Reflux DiseaseThe Journal of Pediatrics, 2009
- Apnea, bradycardia and desaturation in preterm infants before and after feedingJournal of Perinatology, 2009
- The gastric HK-ATPase: structure, function, and inhibitionPflügers Archiv - European Journal of Physiology, 2008
- The Gastric H,K ATPase as a Drug TargetJournal of Clinical Gastroenterology, 2007
- Pharmacokinetics of Proton Pump Inhibitors in ChildrenClinical Pharmacokinetics, 2005
- The Use of Proton Pump Inhibitors in ChildrenPediatric Drugs, 2003